Options mapped

Neuroendocrine tumor (NET): options by country

Sourced options by country plus visit-prep questions for Neuroendocrine tumor (NET). Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedSolid tumorLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

Is the tumor pancreatic NET, GI NET, foregut/midgut/hindgut GEP-NET, or another NET subtype?
Has SSTR imaging shown receptor-positive disease if PRRT is being discussed?
Are symptoms from hormone secretion, tumor bulk, liver metastases, or treatment side effects driving the treatment goal?
Does the tumor meet the EMA subtype and grade/functionality wording for the therapy being discussed?

Trial-search terms to discuss

Neuroendocrine tumor (NET) clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

Iobenguane I 131 (Azedra); belzutifan (Welireg)[1]FDA-approvedIobenguane-scan positive status required for iobenguane I 131 (Azedra); no mutation biomarker stated for belzutifan PPGL FDA approval; Unresectable, locally advanced, or metastatic PPGL requiring systemic anticancer therapy for Azedra; locally advanced, unresectable, or metastatic PPGL for belzutifan. · Azedra requires iobenguane scan positivity and systemic anticancer therapy need; source label may not reflect manufacturing availability. Belzutifan source is an FDA approval notice and not a full local access/reimbursement determination. No claim is made for countries outside the United States. Confidence/conflicts: High for U.S. labeled/approved indications; Azedra current commercial availability remains a follow-up gap because label and access may diverge.
Iobenguane I 131 (Azedra); belzutifan (Welireg)[1]FDA-approvedIobenguane-scan positive status required for iobenguane I 131 (Azedra); no mutation biomarker stated for belzutifan PPGL FDA approval; Unresectable, locally advanced, or metastatic PPGL requiring systemic anticancer therapy for Azedra; locally advanced, unresectable, or metastatic PPGL for belzutifan. · Azedra requires iobenguane scan positivity and systemic anticancer therapy need; source label may not reflect manufacturing availability. Belzutifan source is an FDA approval notice and not a full local access/reimbursement determination. No claim is made for countries outside the United States. Confidence/conflicts: High for U.S. labeled/approved indications; Azedra current commercial availability remains a follow-up gap because label and access may diverge.

European Union

Lutetium (177Lu) oxodotreotide / lutetium Lu 177 dotatate (Lutathera); everolimus (Afinitor); sunitinib (Sutent or sunitinib products)[2]EMA authorisedSomatostatin receptor expression for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus indication; no mutation biomarker required by fetched EMA pages; Unresectable, metastatic, progressive, or treatment-refractory GEP-NET contexts as stated by EMA; pancreatic NET and non-functional GI/lung NET settings for everolimus; pancreatic NET for sunitinib. · EMA central authorization does not establish reimbursement or availability in Germany, France, or other EU member states. Lutathera requires somatostatin-receptor expression; everolimus and sunitinib indications are subtype-limited. Confidence/conflicts: High for EMA authorization text; member-state reimbursement remains a gap.
Lutetium (177Lu) oxodotreotide / lutetium Lu 177 dotatate (Lutathera); everolimus (Afinitor); sunitinib (Sutent or sunitinib products)[2]EMA authorisedSomatostatin receptor expression for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus indication; no mutation biomarker required by fetched EMA pages; Unresectable, metastatic, progressive, or treatment-refractory GEP-NET contexts as stated by EMA; pancreatic NET and non-functional GI/lung NET settings for everolimus; pancreatic NET for sunitinib. · EMA central authorization does not establish reimbursement or availability in Germany, France, or other EU member states. Lutathera requires somatostatin-receptor expression; everolimus and sunitinib indications are subtype-limited. Confidence/conflicts: High for EMA authorization text; member-state reimbursement remains a gap.

United Kingdom

Lutetium (177Lu) oxodotreotide (Lutathera); everolimus (Afinitor); sunitinib (Sutent); best supportive care comparator context [3]ApprovedSomatostatin receptor-positive status for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus as stated by NICE; no mutation biomarker required by fetched NICE recommendations; Unresectable or metastatic progressive GEP-NET; pancreatic NET progressive disease; non-functional GI or lung NET progressive disease, as specified in NICE recommendations. · NICE recommendations mainly apply to England and Wales NHS commissioning contexts and do not equal MHRA label review. Commercial-arrangement and patient-access-scheme conditions apply. Scotland, Northern Ireland, private access, and current local commissioning details need separate verification. Confidence/conflicts: High for NICE recommendations; devolved UK commissioning and current MHRA label specifics remain active gaps.
Lutetium (177Lu) oxodotreotide (Lutathera); everolimus (Afinitor); sunitinib (Sutent); best supportive care comparator context [3]ApprovedSomatostatin receptor-positive status for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus as stated by NICE; no mutation biomarker required by fetched NICE recommendations; Unresectable or metastatic progressive GEP-NET; pancreatic NET progressive disease; non-functional GI or lung NET progressive disease, as specified in NICE recommendations. · NICE recommendations mainly apply to England and Wales NHS commissioning contexts and do not equal MHRA label review. Commercial-arrangement and patient-access-scheme conditions apply. Scotland, Northern Ireland, private access, and current local commissioning details need separate verification. Confidence/conflicts: High for NICE recommendations; devolved UK commissioning and current MHRA label specifics remain active gaps.
Lutetium (177Lu) oxodotreotide (Lutathera); everolimus (Afinitor); sunitinib (Sutent); best supportive care comparator context [3]ApprovedSomatostatin receptor-positive status for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus as stated by NICE; no mutation biomarker required by fetched NICE recommendations; Unresectable or metastatic progressive GEP-NET; pancreatic NET progressive disease; non-functional GI or lung NET progressive disease, as specified in NICE recommendations. · NICE recommendations mainly apply to England and Wales NHS commissioning contexts and do not equal MHRA label review. Commercial-arrangement and patient-access-scheme conditions apply. Scotland, Northern Ireland, private access, and current local commissioning details need separate verification. Confidence/conflicts: High for NICE recommendations; devolved UK commissioning and current MHRA label specifics remain active gaps.

Sources

U.S. Food and Drug Administration / Drugs@FDA — official drug label · official drug label
European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
NICE — technology appraisal final appraisal document · technology appraisal final appraisal document

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

Preoperative catecholamine blockade; surgery; chemotherapy; radiofrequency ablation; cryoablation; radiation therapy; palliative therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No mutation biomarker required by fetched NCI framework; hereditary syndromes and genetic testing are discussed as risk/management context; Localized, regional, metastatic, unresectable, and recurrent pheochromocytoma/paraganglioma contexts. · NCI PDQ is an evidence summary, not a regulator or payer source. It notes limited phase 2 clinical-trial data and that survival impact is not known for many approaches. It does not provide a personalized sequence or eligibility determination. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific options require separate label sources. National Cancer Institute (NCI) — national cancer agency evidence summary
Preoperative catecholamine blockade; surgery; chemotherapy; radiofrequency ablation; cryoablation; radiation therapy; palliative therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No mutation biomarker required by fetched NCI framework; hereditary syndromes and genetic testing are discussed as risk/management context; Localized, regional, metastatic, unresectable, and recurrent pheochromocytoma/paraganglioma contexts. · NCI PDQ is an evidence summary, not a regulator or payer source. It notes limited phase 2 clinical-trial data and that survival impact is not known for many approaches. It does not provide a personalized sequence or eligibility determination. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific options require separate label sources. National Cancer Institute (NCI) — national cancer agency evidence summary
Preoperative catecholamine blockade; surgery; chemotherapy; radiofrequency ablation; cryoablation; radiation therapy; palliative therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No mutation biomarker required by fetched NCI framework; hereditary syndromes and genetic testing are discussed as risk/management context; Localized, regional, metastatic, unresectable, and recurrent pheochromocytoma/paraganglioma contexts. · NCI PDQ is an evidence summary, not a regulator or payer source. It notes limited phase 2 clinical-trial data and that survival impact is not known for many approaches. It does not provide a personalized sequence or eligibility determination. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific options require separate label sources. National Cancer Institute (NCI) — national cancer agency evidence summary
Preoperative catecholamine blockade; surgery; chemotherapy; radiofrequency ablation; cryoablation; radiation therapy; palliative therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No mutation biomarker required by fetched NCI framework; hereditary syndromes and genetic testing are discussed as risk/management context; Localized, regional, metastatic, unresectable, and recurrent pheochromocytoma/paraganglioma contexts. · NCI PDQ is an evidence summary, not a regulator or payer source. It notes limited phase 2 clinical-trial data and that survival impact is not known for many approaches. It does not provide a personalized sequence or eligibility determination. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific options require separate label sources. National Cancer Institute (NCI) — national cancer agency evidence summary
Preoperative catecholamine blockade; surgery; chemotherapy; radiofrequency ablation; cryoablation; radiation therapy; palliative therapy; clinical trialsClinical trialClinical trialInvestigationalUnited States · No mutation biomarker required by fetched NCI framework; hereditary syndromes and genetic testing are discussed as risk/management context; Localized, regional, metastatic, unresectable, and recurrent pheochromocytoma/paraganglioma contexts. · NCI PDQ is an evidence summary, not a regulator or payer source. It notes limited phase 2 clinical-trial data and that survival impact is not known for many approaches. It does not provide a personalized sequence or eligibility determination. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific options require separate label sources. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; somatostatin analogues; hepatic-metastasis treatments; radionuclides including lutetium Lu 177 dotatate (Lutathera); symptomatic therapy; everolimus (Afinitor); sunitinib (Sutent); clinical trialsClinical trialClinical trialInvestigationalUnited States · Somatostatin receptor (SSTR)-positive status for lutetium Lu 177 dotatate; non-functional status for GI/lung everolimus label context; no mutation biomarker required by fetched sources; Gastrointestinal NET treatment framework; SSTR-positive GEP-NETs in adults and pediatric patients 12 years and older; progressive pancreatic NET; progressive well-differentiated non-functional GI NET; unresectable, locally advanced, or metastatic settings as stated in labels. · NCI PDQ is an evidence summary and does not establish payer coverage. FDA/DailyMed labels do not imply individual eligibility, center access, receptor positivity, tumor grade, functional status, or sequencing among therapies. Sunitinib label context is pancreatic NET, not all GEP-NETs. Confidence/conflicts: High for U.S. evidence-summary and labeled indications; sequencing and reimbursement require separate local verification. DailyMed / U.S. FDA label — official drug label
Surgery; somatostatin analogues; hepatic-metastasis treatments; radionuclides including lutetium Lu 177 dotatate (Lutathera); symptomatic therapy; everolimus (Afinitor); sunitinib (Sutent); clinical trialsClinical trialClinical trialInvestigationalUnited States · Somatostatin receptor (SSTR)-positive status for lutetium Lu 177 dotatate; non-functional status for GI/lung everolimus label context; no mutation biomarker required by fetched sources; Gastrointestinal NET treatment framework; SSTR-positive GEP-NETs in adults and pediatric patients 12 years and older; progressive pancreatic NET; progressive well-differentiated non-functional GI NET; unresectable, locally advanced, or metastatic settings as stated in labels. · NCI PDQ is an evidence summary and does not establish payer coverage. FDA/DailyMed labels do not imply individual eligibility, center access, receptor positivity, tumor grade, functional status, or sequencing among therapies. Sunitinib label context is pancreatic NET, not all GEP-NETs. Confidence/conflicts: High for U.S. evidence-summary and labeled indications; sequencing and reimbursement require separate local verification. DailyMed / U.S. FDA label — official drug label
Surgery; somatostatin analogues; hepatic-metastasis treatments; radionuclides including lutetium Lu 177 dotatate (Lutathera); symptomatic therapy; everolimus (Afinitor); sunitinib (Sutent); clinical trialsClinical trialClinical trialInvestigationalUnited States · Somatostatin receptor (SSTR)-positive status for lutetium Lu 177 dotatate; non-functional status for GI/lung everolimus label context; no mutation biomarker required by fetched sources; Gastrointestinal NET treatment framework; SSTR-positive GEP-NETs in adults and pediatric patients 12 years and older; progressive pancreatic NET; progressive well-differentiated non-functional GI NET; unresectable, locally advanced, or metastatic settings as stated in labels. · NCI PDQ is an evidence summary and does not establish payer coverage. FDA/DailyMed labels do not imply individual eligibility, center access, receptor positivity, tumor grade, functional status, or sequencing among therapies. Sunitinib label context is pancreatic NET, not all GEP-NETs. Confidence/conflicts: High for U.S. evidence-summary and labeled indications; sequencing and reimbursement require separate local verification. DailyMed / U.S. FDA label — official drug label
Surgery; somatostatin analogues; hepatic-metastasis treatments; radionuclides including lutetium Lu 177 dotatate (Lutathera); symptomatic therapy; everolimus (Afinitor); sunitinib (Sutent); clinical trialsClinical trialClinical trialInvestigationalUnited States · Somatostatin receptor (SSTR)-positive status for lutetium Lu 177 dotatate; non-functional status for GI/lung everolimus label context; no mutation biomarker required by fetched sources; Gastrointestinal NET treatment framework; SSTR-positive GEP-NETs in adults and pediatric patients 12 years and older; progressive pancreatic NET; progressive well-differentiated non-functional GI NET; unresectable, locally advanced, or metastatic settings as stated in labels. · NCI PDQ is an evidence summary and does not establish payer coverage. FDA/DailyMed labels do not imply individual eligibility, center access, receptor positivity, tumor grade, functional status, or sequencing among therapies. Sunitinib label context is pancreatic NET, not all GEP-NETs. Confidence/conflicts: High for U.S. evidence-summary and labeled indications; sequencing and reimbursement require separate local verification. DailyMed / U.S. FDA label — official drug label
Surgery; somatostatin analogues; hepatic-metastasis treatments; radionuclides including lutetium Lu 177 dotatate (Lutathera); symptomatic therapy; everolimus (Afinitor); sunitinib (Sutent); clinical trialsClinical trialClinical trialInvestigationalUnited States · Somatostatin receptor (SSTR)-positive status for lutetium Lu 177 dotatate; non-functional status for GI/lung everolimus label context; no mutation biomarker required by fetched sources; Gastrointestinal NET treatment framework; SSTR-positive GEP-NETs in adults and pediatric patients 12 years and older; progressive pancreatic NET; progressive well-differentiated non-functional GI NET; unresectable, locally advanced, or metastatic settings as stated in labels. · NCI PDQ is an evidence summary and does not establish payer coverage. FDA/DailyMed labels do not imply individual eligibility, center access, receptor positivity, tumor grade, functional status, or sequencing among therapies. Sunitinib label context is pancreatic NET, not all GEP-NETs. Confidence/conflicts: High for U.S. evidence-summary and labeled indications; sequencing and reimbursement require separate local verification. DailyMed / U.S. FDA label — official drug label
Surgery/adrenalectomy; phenoxybenzamine or similar preoperative blockade; MIBG radioisotope therapy; DOTATATE radionuclide therapy; external beam radiotherapy; CVD chemotherapy (cyclophosphamide, vincristine, dacarbazine); targeted drugs studied including sunitinib and cabozantinib; watch-and-wait/active surveillance; radiofrequency ablation and chemoembolisationClinical trialClinical trialInvestigationalUnited Kingdom · MIBG uptake for MIBG treatment; DOTATATE uptake for DOTATATE radionuclide therapy; no mutation biomarker required by fetched UK source; Non-spread disease; recurrent or spread phaeochromocytoma; MIBG-avid or DOTATATE-avid disease; bone spread symptom-control context; spread disease not responding to MIBG/DOTATATE. · Cancer Research UK is a patient-information source, not NICE/MHRA regulator guidance. It says DOTATATE treatment is newer and not available in all hospitals, and that targeted drugs have been studied but comparative effectiveness versus chemotherapy is uncertain. No claim is made for automatic NHS access. Confidence/conflicts: Medium-high for UK treatment-information framework; NICE/MHRA and hospital availability remain active gaps. Cancer Research UK — UK cancer information / treatment information
Surgery/adrenalectomy; phenoxybenzamine or similar preoperative blockade; MIBG radioisotope therapy; DOTATATE radionuclide therapy; external beam radiotherapy; CVD chemotherapy (cyclophosphamide, vincristine, dacarbazine); targeted drugs studied including sunitinib and cabozantinib; watch-and-wait/active surveillance; radiofrequency ablation and chemoembolisationClinical trialClinical trialInvestigationalUnited Kingdom · MIBG uptake for MIBG treatment; DOTATATE uptake for DOTATATE radionuclide therapy; no mutation biomarker required by fetched UK source; Non-spread disease; recurrent or spread phaeochromocytoma; MIBG-avid or DOTATATE-avid disease; bone spread symptom-control context; spread disease not responding to MIBG/DOTATATE. · Cancer Research UK is a patient-information source, not NICE/MHRA regulator guidance. It says DOTATATE treatment is newer and not available in all hospitals, and that targeted drugs have been studied but comparative effectiveness versus chemotherapy is uncertain. No claim is made for automatic NHS access. Confidence/conflicts: Medium-high for UK treatment-information framework; NICE/MHRA and hospital availability remain active gaps. Cancer Research UK — UK cancer information / treatment information
Surgery/adrenalectomy; phenoxybenzamine or similar preoperative blockade; MIBG radioisotope therapy; DOTATATE radionuclide therapy; external beam radiotherapy; CVD chemotherapy (cyclophosphamide, vincristine, dacarbazine); targeted drugs studied including sunitinib and cabozantinib; watch-and-wait/active surveillance; radiofrequency ablation and chemoembolisationClinical trialClinical trialInvestigationalUnited Kingdom · MIBG uptake for MIBG treatment; DOTATATE uptake for DOTATATE radionuclide therapy; no mutation biomarker required by fetched UK source; Non-spread disease; recurrent or spread phaeochromocytoma; MIBG-avid or DOTATATE-avid disease; bone spread symptom-control context; spread disease not responding to MIBG/DOTATATE. · Cancer Research UK is a patient-information source, not NICE/MHRA regulator guidance. It says DOTATATE treatment is newer and not available in all hospitals, and that targeted drugs have been studied but comparative effectiveness versus chemotherapy is uncertain. No claim is made for automatic NHS access. Confidence/conflicts: Medium-high for UK treatment-information framework; NICE/MHRA and hospital availability remain active gaps. Cancer Research UK — UK cancer information / treatment information
Surgery/adrenalectomy; phenoxybenzamine or similar preoperative blockade; MIBG radioisotope therapy; DOTATATE radionuclide therapy; external beam radiotherapy; CVD chemotherapy (cyclophosphamide, vincristine, dacarbazine); targeted drugs studied including sunitinib and cabozantinib; watch-and-wait/active surveillance; radiofrequency ablation and chemoembolisationClinical trialClinical trialInvestigationalUnited Kingdom · MIBG uptake for MIBG treatment; DOTATATE uptake for DOTATATE radionuclide therapy; no mutation biomarker required by fetched UK source; Non-spread disease; recurrent or spread phaeochromocytoma; MIBG-avid or DOTATATE-avid disease; bone spread symptom-control context; spread disease not responding to MIBG/DOTATATE. · Cancer Research UK is a patient-information source, not NICE/MHRA regulator guidance. It says DOTATATE treatment is newer and not available in all hospitals, and that targeted drugs have been studied but comparative effectiveness versus chemotherapy is uncertain. No claim is made for automatic NHS access. Confidence/conflicts: Medium-high for UK treatment-information framework; NICE/MHRA and hospital availability remain active gaps. Cancer Research UK — UK cancer information / treatment information
Surgery/adrenalectomy; phenoxybenzamine or similar preoperative blockade; MIBG radioisotope therapy; DOTATATE radionuclide therapy; external beam radiotherapy; CVD chemotherapy (cyclophosphamide, vincristine, dacarbazine); targeted drugs studied including sunitinib and cabozantinib; watch-and-wait/active surveillance; radiofrequency ablation and chemoembolisationClinical trialClinical trialInvestigationalUnited Kingdom · MIBG uptake for MIBG treatment; DOTATATE uptake for DOTATATE radionuclide therapy; no mutation biomarker required by fetched UK source; Non-spread disease; recurrent or spread phaeochromocytoma; MIBG-avid or DOTATATE-avid disease; bone spread symptom-control context; spread disease not responding to MIBG/DOTATATE. · Cancer Research UK is a patient-information source, not NICE/MHRA regulator guidance. It says DOTATATE treatment is newer and not available in all hospitals, and that targeted drugs have been studied but comparative effectiveness versus chemotherapy is uncertain. No claim is made for automatic NHS access. Confidence/conflicts: Medium-high for UK treatment-information framework; NICE/MHRA and hospital availability remain active gaps. Cancer Research UK — UK cancer information / treatment information
Belzutifan / MK-6482 (Welireg)Clinical trial · NCT04924075Clinical trialTrial only (NCT04924075)Japan · HIF-2alpha-related genetic alterations for one study cohort; VHL disease-associated tumor cohort; PPGL cohort does not require a mutation in the fetched registry summary; Advanced PPGL and other study cohorts including pNET, VHL-associated tumors, advanced wild-type GIST, or HIF-2alpha-related solid tumors. · Registry listing does not establish PMDA or Russian regulator approval, reimbursement, routine access, or individual eligibility. The study has multiple cohorts, so cohort assignment must be confirmed for PPGL. Confidence/conflicts: High for registry-listed Japan/Russia sites; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482 (Welireg)Clinical trial · NCT04924075Clinical trialTrial only (NCT04924075)Japan · HIF-2alpha-related genetic alterations for one study cohort; VHL disease-associated tumor cohort; PPGL cohort does not require a mutation in the fetched registry summary; Advanced PPGL and other study cohorts including pNET, VHL-associated tumors, advanced wild-type GIST, or HIF-2alpha-related solid tumors. · Registry listing does not establish PMDA or Russian regulator approval, reimbursement, routine access, or individual eligibility. The study has multiple cohorts, so cohort assignment must be confirmed for PPGL. Confidence/conflicts: High for registry-listed Japan/Russia sites; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
PDR001; sunitinibClinical trial · NCT02955069Clinical trialTrial only (registry)Japan · Non-functional status for well-differentiated pancreatic/GI/thoracic NET cohorts in NCT02955069; no mutation biomarker required by fetched Japan registry records; Advanced or metastatic well-differentiated non-functional pancreatic/GI/thoracic NET; poorly differentiated GEP-NEC; advanced well-differentiated pancreatic NET. · Registry records are completed and do not establish PMDA approval, reimbursement, current access, or individual eligibility. PDR001 is investigational in this context; sunitinib trial listing is not a current Japanese label source. Confidence/conflicts: Medium-high for Japan registry-listed trial activity; current PMDA status remains unverified. ClinicalTrials.gov — clinical-trial registry
PDR001; sunitinibClinical trial · NCT02955069Clinical trialTrial only (registry)Japan · Non-functional status for well-differentiated pancreatic/GI/thoracic NET cohorts in NCT02955069; no mutation biomarker required by fetched Japan registry records; Advanced or metastatic well-differentiated non-functional pancreatic/GI/thoracic NET; poorly differentiated GEP-NEC; advanced well-differentiated pancreatic NET. · Registry records are completed and do not establish PMDA approval, reimbursement, current access, or individual eligibility. PDR001 is investigational in this context; sunitinib trial listing is not a current Japanese label source. Confidence/conflicts: Medium-high for Japan registry-listed trial activity; current PMDA status remains unverified. ClinicalTrials.gov — clinical-trial registry
PDR001; sunitinibClinical trial · NCT02955069Clinical trialTrial only (registry)Japan · Non-functional status for well-differentiated pancreatic/GI/thoracic NET cohorts in NCT02955069; no mutation biomarker required by fetched Japan registry records; Advanced or metastatic well-differentiated non-functional pancreatic/GI/thoracic NET; poorly differentiated GEP-NEC; advanced well-differentiated pancreatic NET. · Registry records are completed and do not establish PMDA approval, reimbursement, current access, or individual eligibility. PDR001 is investigational in this context; sunitinib trial listing is not a current Japanese label source. Confidence/conflicts: Medium-high for Japan registry-listed trial activity; current PMDA status remains unverified. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; phenoxybenzamine preoperative alpha-adrenergic blockade; RAD001 (everolimus); adrenal-disease cohort hormone and imaging studyClinical trial · NCT04924075Clinical trialTrial only (registry)Korea · No mutation biomarker required by fetched Korea registry records; Advanced PPGL trial context; normotensive pheochromocytoma perioperative management; pheochromocytoma/extra-adrenal paraganglioma targeted therapy study; adrenal disease evidence-generation contexts. · Registry records do not establish MFDS approval, reimbursement, routine access, or standard-of-care changes. The alpha-blockade study tests omission in normotensive pheochromocytoma and should not be generalized to catecholamine-secreting or hypertensive disease. Confidence/conflicts: High for Korea registry-listed PPGL activity; MFDS/routine access remains unverified. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; phenoxybenzamine preoperative alpha-adrenergic blockade; RAD001 (everolimus); adrenal-disease cohort hormone and imaging studyClinical trial · NCT04924075Clinical trialTrial only (registry)Korea · No mutation biomarker required by fetched Korea registry records; Advanced PPGL trial context; normotensive pheochromocytoma perioperative management; pheochromocytoma/extra-adrenal paraganglioma targeted therapy study; adrenal disease evidence-generation contexts. · Registry records do not establish MFDS approval, reimbursement, routine access, or standard-of-care changes. The alpha-blockade study tests omission in normotensive pheochromocytoma and should not be generalized to catecholamine-secreting or hypertensive disease. Confidence/conflicts: High for Korea registry-listed PPGL activity; MFDS/routine access remains unverified. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; phenoxybenzamine preoperative alpha-adrenergic blockade; RAD001 (everolimus); adrenal-disease cohort hormone and imaging studyClinical trial · NCT04924075Clinical trialTrial only (registry)Korea · No mutation biomarker required by fetched Korea registry records; Advanced PPGL trial context; normotensive pheochromocytoma perioperative management; pheochromocytoma/extra-adrenal paraganglioma targeted therapy study; adrenal disease evidence-generation contexts. · Registry records do not establish MFDS approval, reimbursement, routine access, or standard-of-care changes. The alpha-blockade study tests omission in normotensive pheochromocytoma and should not be generalized to catecholamine-secreting or hypertensive disease. Confidence/conflicts: High for Korea registry-listed PPGL activity; MFDS/routine access remains unverified. ClinicalTrials.gov — clinical-trial registry
Lutetium Lu 177 dotatate / Lutathera; TEMCAP (temozolomide/capecitabine); lanreotide autogel; RYZ101; everolimus; sunitinib; octreotide; lanreotideClinical trial · NCT04946305Clinical trialTrial only (registry)Korea · SSTR-positive status for Lutathera and Lu-DOTA-TATE/RYZ101 studies; low Ki-67 grade 3 context for TEMCAP study; no mutation biomarker required by fetched Korea records; SSTR-positive GEP-NET post-marketing surveillance; grade 3 low Ki-67 GEP-NET; inoperable SSTR-positive well-differentiated GEP-NET after Lu-177 SSA; grade 1/2 advanced GEP-NET; grade 2/3 advanced GEP-NET. · Registry records do not establish MFDS approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. The Lutathera post-marketing surveillance record suggests local post-approval safety monitoring but is not itself a regulator label. Confidence/conflicts: High for Korea registry-listed GEP-NET activity; MFDS approval and reimbursement require regulator verification. ClinicalTrials.gov — clinical-trial registry
Lutetium Lu 177 dotatate / Lutathera; TEMCAP (temozolomide/capecitabine); lanreotide autogel; RYZ101; everolimus; sunitinib; octreotide; lanreotideClinical trial · NCT04946305Clinical trialTrial only (registry)Korea · SSTR-positive status for Lutathera and Lu-DOTA-TATE/RYZ101 studies; low Ki-67 grade 3 context for TEMCAP study; no mutation biomarker required by fetched Korea records; SSTR-positive GEP-NET post-marketing surveillance; grade 3 low Ki-67 GEP-NET; inoperable SSTR-positive well-differentiated GEP-NET after Lu-177 SSA; grade 1/2 advanced GEP-NET; grade 2/3 advanced GEP-NET. · Registry records do not establish MFDS approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. The Lutathera post-marketing surveillance record suggests local post-approval safety monitoring but is not itself a regulator label. Confidence/conflicts: High for Korea registry-listed GEP-NET activity; MFDS approval and reimbursement require regulator verification. ClinicalTrials.gov — clinical-trial registry
Lutetium Lu 177 dotatate / Lutathera; TEMCAP (temozolomide/capecitabine); lanreotide autogel; RYZ101; everolimus; sunitinib; octreotide; lanreotideClinical trial · NCT04946305Clinical trialTrial only (registry)Korea · SSTR-positive status for Lutathera and Lu-DOTA-TATE/RYZ101 studies; low Ki-67 grade 3 context for TEMCAP study; no mutation biomarker required by fetched Korea records; SSTR-positive GEP-NET post-marketing surveillance; grade 3 low Ki-67 GEP-NET; inoperable SSTR-positive well-differentiated GEP-NET after Lu-177 SSA; grade 1/2 advanced GEP-NET; grade 2/3 advanced GEP-NET. · Registry records do not establish MFDS approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. The Lutathera post-marketing surveillance record suggests local post-approval safety monitoring but is not itself a regulator label. Confidence/conflicts: High for Korea registry-listed GEP-NET activity; MFDS approval and reimbursement require regulator verification. ClinicalTrials.gov — clinical-trial registry
Lutetium Lu 177 dotatate / Lutathera; TEMCAP (temozolomide/capecitabine); lanreotide autogel; RYZ101; everolimus; sunitinib; octreotide; lanreotideClinical trial · NCT04946305Clinical trialTrial only (registry)Korea · SSTR-positive status for Lutathera and Lu-DOTA-TATE/RYZ101 studies; low Ki-67 grade 3 context for TEMCAP study; no mutation biomarker required by fetched Korea records; SSTR-positive GEP-NET post-marketing surveillance; grade 3 low Ki-67 GEP-NET; inoperable SSTR-positive well-differentiated GEP-NET after Lu-177 SSA; grade 1/2 advanced GEP-NET; grade 2/3 advanced GEP-NET. · Registry records do not establish MFDS approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. The Lutathera post-marketing surveillance record suggests local post-approval safety monitoring but is not itself a regulator label. Confidence/conflicts: High for Korea registry-listed GEP-NET activity; MFDS approval and reimbursement require regulator verification. ClinicalTrials.gov — clinical-trial registry
Lutetium Lu 177 dotatate / Lutathera; TEMCAP (temozolomide/capecitabine); lanreotide autogel; RYZ101; everolimus; sunitinib; octreotide; lanreotideClinical trial · NCT04946305Clinical trialTrial only (registry)Korea · SSTR-positive status for Lutathera and Lu-DOTA-TATE/RYZ101 studies; low Ki-67 grade 3 context for TEMCAP study; no mutation biomarker required by fetched Korea records; SSTR-positive GEP-NET post-marketing surveillance; grade 3 low Ki-67 GEP-NET; inoperable SSTR-positive well-differentiated GEP-NET after Lu-177 SSA; grade 1/2 advanced GEP-NET; grade 2/3 advanced GEP-NET. · Registry records do not establish MFDS approval, reimbursement, routine access, active enrollment for all studies, or individual eligibility. The Lutathera post-marketing surveillance record suggests local post-approval safety monitoring but is not itself a regulator label. Confidence/conflicts: High for Korea registry-listed GEP-NET activity; MFDS approval and reimbursement require regulator verification. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; anlotinib hydrochloride; temozolomide; 18F-MFBG; 68Ga-DOTATATEClinical trial · NCT04924075Clinical trialTrial only (registry)China · No mutation biomarker required by fetched China treatment registry records; imaging studies involve 18F-MFBG and 68Ga-DOTATATE uptake evaluation; Advanced PPGL; neoadjuvant PPGL; metastatic or locally advanced PPGL; metastatic malignant pheochromocytoma/paraganglioma; imaging evaluation. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some China records have unknown status despite listed recruiting site status. Imaging studies support diagnostic/selection context, not therapeutic availability. Confidence/conflicts: High for China registry-listed PPGL activity; NMPA approval/access not established. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; anlotinib hydrochloride; temozolomide; 18F-MFBG; 68Ga-DOTATATEClinical trial · NCT04924075Clinical trialTrial only (registry)China · No mutation biomarker required by fetched China treatment registry records; imaging studies involve 18F-MFBG and 68Ga-DOTATATE uptake evaluation; Advanced PPGL; neoadjuvant PPGL; metastatic or locally advanced PPGL; metastatic malignant pheochromocytoma/paraganglioma; imaging evaluation. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some China records have unknown status despite listed recruiting site status. Imaging studies support diagnostic/selection context, not therapeutic availability. Confidence/conflicts: High for China registry-listed PPGL activity; NMPA approval/access not established. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; anlotinib hydrochloride; temozolomide; 18F-MFBG; 68Ga-DOTATATEClinical trial · NCT04924075Clinical trialTrial only (registry)China · No mutation biomarker required by fetched China treatment registry records; imaging studies involve 18F-MFBG and 68Ga-DOTATATE uptake evaluation; Advanced PPGL; neoadjuvant PPGL; metastatic or locally advanced PPGL; metastatic malignant pheochromocytoma/paraganglioma; imaging evaluation. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some China records have unknown status despite listed recruiting site status. Imaging studies support diagnostic/selection context, not therapeutic availability. Confidence/conflicts: High for China registry-listed PPGL activity; NMPA approval/access not established. ClinicalTrials.gov — clinical-trial registry
Belzutifan / MK-6482; anlotinib hydrochloride; temozolomide; 18F-MFBG; 68Ga-DOTATATEClinical trial · NCT04924075Clinical trialTrial only (registry)China · No mutation biomarker required by fetched China treatment registry records; imaging studies involve 18F-MFBG and 68Ga-DOTATATE uptake evaluation; Advanced PPGL; neoadjuvant PPGL; metastatic or locally advanced PPGL; metastatic malignant pheochromocytoma/paraganglioma; imaging evaluation. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some China records have unknown status despite listed recruiting site status. Imaging studies support diagnostic/selection context, not therapeutic availability. Confidence/conflicts: High for China registry-listed PPGL activity; NMPA approval/access not established. ClinicalTrials.gov — clinical-trial registry
Octreotide subcutaneous injection (SYHX2008) and Sandostatin LAR; 177Lu-edotreotide PRRT; CAPTEM; everolimus; FOLFOX; famitinib; lutetium [177Lu] oxodotreotide injection; sirolimus albumin-bound plus octreotide long-acting injection; lanreotide autogelClinical trial · NCT06505395Clinical trialTrial only (registry)China · Somatostatin receptor-positive status for Lu-177 oxodotreotide studies where specified; no mutation biomarker required by fetched China registry records; Advanced/metastatic GEP-NET; well-differentiated aggressive grade 2/3 GEP-NET; locally advanced/metastatic SSTR-positive G2/G3 GEP-NET; metastatic GEP-NET; Chinese GEP-NET participant treatment studies. · Registry records do not establish NMPA approval, reimbursement, routine availability, active enrollment for all studies, or individual eligibility. One famitinib record is terminated and one Lu-177 dotatate record has unknown status. Confidence/conflicts: High for China registry-listed GEP-NET study activity; NMPA approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Octreotide subcutaneous injection (SYHX2008) and Sandostatin LAR; 177Lu-edotreotide PRRT; CAPTEM; everolimus; FOLFOX; famitinib; lutetium [177Lu] oxodotreotide injection; sirolimus albumin-bound plus octreotide long-acting injection; lanreotide autogelClinical trial · NCT06505395Clinical trialTrial only (registry)China · Somatostatin receptor-positive status for Lu-177 oxodotreotide studies where specified; no mutation biomarker required by fetched China registry records; Advanced/metastatic GEP-NET; well-differentiated aggressive grade 2/3 GEP-NET; locally advanced/metastatic SSTR-positive G2/G3 GEP-NET; metastatic GEP-NET; Chinese GEP-NET participant treatment studies. · Registry records do not establish NMPA approval, reimbursement, routine availability, active enrollment for all studies, or individual eligibility. One famitinib record is terminated and one Lu-177 dotatate record has unknown status. Confidence/conflicts: High for China registry-listed GEP-NET study activity; NMPA approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Octreotide subcutaneous injection (SYHX2008) and Sandostatin LAR; 177Lu-edotreotide PRRT; CAPTEM; everolimus; FOLFOX; famitinib; lutetium [177Lu] oxodotreotide injection; sirolimus albumin-bound plus octreotide long-acting injection; lanreotide autogelClinical trial · NCT06505395Clinical trialTrial only (registry)China · Somatostatin receptor-positive status for Lu-177 oxodotreotide studies where specified; no mutation biomarker required by fetched China registry records; Advanced/metastatic GEP-NET; well-differentiated aggressive grade 2/3 GEP-NET; locally advanced/metastatic SSTR-positive G2/G3 GEP-NET; metastatic GEP-NET; Chinese GEP-NET participant treatment studies. · Registry records do not establish NMPA approval, reimbursement, routine availability, active enrollment for all studies, or individual eligibility. One famitinib record is terminated and one Lu-177 dotatate record has unknown status. Confidence/conflicts: High for China registry-listed GEP-NET study activity; NMPA approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Octreotide subcutaneous injection (SYHX2008) and Sandostatin LAR; 177Lu-edotreotide PRRT; CAPTEM; everolimus; FOLFOX; famitinib; lutetium [177Lu] oxodotreotide injection; sirolimus albumin-bound plus octreotide long-acting injection; lanreotide autogelClinical trial · NCT06505395Clinical trialTrial only (registry)China · Somatostatin receptor-positive status for Lu-177 oxodotreotide studies where specified; no mutation biomarker required by fetched China registry records; Advanced/metastatic GEP-NET; well-differentiated aggressive grade 2/3 GEP-NET; locally advanced/metastatic SSTR-positive G2/G3 GEP-NET; metastatic GEP-NET; Chinese GEP-NET participant treatment studies. · Registry records do not establish NMPA approval, reimbursement, routine availability, active enrollment for all studies, or individual eligibility. One famitinib record is terminated and one Lu-177 dotatate record has unknown status. Confidence/conflicts: High for China registry-listed GEP-NET study activity; NMPA approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Octreotide subcutaneous injection (SYHX2008) and Sandostatin LAR; 177Lu-edotreotide PRRT; CAPTEM; everolimus; FOLFOX; famitinib; lutetium [177Lu] oxodotreotide injection; sirolimus albumin-bound plus octreotide long-acting injection; lanreotide autogelClinical trial · NCT06505395Clinical trialTrial only (registry)China · Somatostatin receptor-positive status for Lu-177 oxodotreotide studies where specified; no mutation biomarker required by fetched China registry records; Advanced/metastatic GEP-NET; well-differentiated aggressive grade 2/3 GEP-NET; locally advanced/metastatic SSTR-positive G2/G3 GEP-NET; metastatic GEP-NET; Chinese GEP-NET participant treatment studies. · Registry records do not establish NMPA approval, reimbursement, routine availability, active enrollment for all studies, or individual eligibility. One famitinib record is terminated and one Lu-177 dotatate record has unknown status. Confidence/conflicts: High for China registry-listed GEP-NET study activity; NMPA approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Everolimus; pasireotide LAR; pasireotide; cabergoline; Sandostatin LAR DepotClinical trial · NCT01374451Clinical trialTrial only (registry)Thailand · No mutation biomarker required by fetched Thailand registry records; Advanced pancreatic NET; advanced pancreatic-origin neuroendocrine tumors; ongoing access context for patients benefiting from pasireotide in prior sponsored studies that included NET. · Thailand records are historical/completed or terminated and do not establish Thai FDA approval, reimbursement, current availability, or eligibility. The pasireotide access study includes multiple diseases and should not be interpreted as a Thailand NET-specific standard therapy source. Confidence/conflicts: Medium for Thailand historical trial/access activity; current Thai regulatory and routine availability status remains unverified. ClinicalTrials.gov — clinical-trial registry
Everolimus; pasireotide LAR; pasireotide; cabergoline; Sandostatin LAR DepotClinical trial · NCT01374451Clinical trialTrial only (registry)Thailand · No mutation biomarker required by fetched Thailand registry records; Advanced pancreatic NET; advanced pancreatic-origin neuroendocrine tumors; ongoing access context for patients benefiting from pasireotide in prior sponsored studies that included NET. · Thailand records are historical/completed or terminated and do not establish Thai FDA approval, reimbursement, current availability, or eligibility. The pasireotide access study includes multiple diseases and should not be interpreted as a Thailand NET-specific standard therapy source. Confidence/conflicts: Medium for Thailand historical trial/access activity; current Thai regulatory and routine availability status remains unverified. ClinicalTrials.gov — clinical-trial registry
Everolimus; pasireotide LAR; pasireotide; cabergoline; Sandostatin LAR DepotClinical trial · NCT01374451Clinical trialTrial only (registry)Thailand · No mutation biomarker required by fetched Thailand registry records; Advanced pancreatic NET; advanced pancreatic-origin neuroendocrine tumors; ongoing access context for patients benefiting from pasireotide in prior sponsored studies that included NET. · Thailand records are historical/completed or terminated and do not establish Thai FDA approval, reimbursement, current availability, or eligibility. The pasireotide access study includes multiple diseases and should not be interpreted as a Thailand NET-specific standard therapy source. Confidence/conflicts: Medium for Thailand historical trial/access activity; current Thai regulatory and routine availability status remains unverified. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.